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Introduction: Interferon Gamma Release Assay (IGRA) has proven to be a useful test
to evaluate the immune response to Mycobacterium tuberculosis antigens in children
over the age of 5 years as an alternative to tuberculin skin testing (TST). Much less is
known about its performance in younger children, who are at higher risk for developing
tuberculosis (TB) disease after exposure. We aimed to evaluate the accuracy of using
IGRA in TB screening in this population.
Methods: Children below the age of 5 years at high risk for TB infection were
prospectively enrolled, to compare the performance of TST and the QuantiFERON-TB
Gold-In-Tube test (QFT). Children were treated in accordance with the diagnosis made
at baseline and followed-up for 12 months.
Results: We included a total of 60 children of which 97 blood samples were available
for analysis. There was 90.72% agreement between TST and QFT (Kappa test 0.59,
moderate agreement). With TST as a reference, the QFT positive predictive value was
0.72 and the negative predictive value 0.93. Discordant results were observed with
6% TST+/QFT– paired tests. When we restricted the comparison of TST and QFT to
non-BCG-vaccinated children, the degree of agreement was more substantial (95%,
Kappa test 0.75) and the negative predictive value was 0.99.We observed 3%discordant
TST–/QFT+ results. All children with active TB disease had concordant positive QFT
results, with QFT values above 4.00 IU/ml.
Conclusion: In a low TB prevalence country, serial testing of QFT was found to produce
a moderate agreement with TST results. False positive QFT results would have been
eliminated by using a higher cutoff without misdiagnosing the children with TB disease.
Some of the false negative QFT results could be explained by false positive TST results
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on consecutive testing. For now the most prudent approach would be to consider
discordant QFT–/TST+ results as false negative QFT results, taking into account the
young age of our population and the potential risk for evolution to active TB disease.
Keywords: tuberculosis, latent tuberculosis infection, tuberculin skin test, interferon gamma release assay,
QuantiFERON, children, contact screening
INTRODUCTION
According to the World Health Organization (WHO), one
million children fell ill with tuberculosis (TB) in 2017. A higher
percentage (15%) of children died from the disease compared to
their share of estimated cases, suggesting their reduced access to
diagnosis and treatment (1).
Following infection, young children progress more frequently
and more rapidly to active TB disease compared to older
children and adults (2–5). Treatment of latent tuberculous
infection (LTBI) reduces the risk of disease progression, which
is especially crucial for young children (6, 7). The WHO
therefore recommends to screen young children (<5 years
old) who have recently been in contact with a person affected
by pulmonary TB and to initiate LTBI treatment even before
infection can be demonstrated. Tuberculin skin testing (TST)
is the recommended method for evaluating young children for
TB infection (1, 7, 8). Difficulties, however, hamper the use
of the TST with result interpretation, the need for a follow-
up visit by the patient and false-positive results caused by
cross-reaction with the Bacillus Calmette-Guérin (BCG) vaccine
and with non-tuberculous mycobacteria (NTM) (9). Another
diagnostic test, the Interferon Gamma Release Assay (IGRA),
is available. IGRA is an in vitro blood test, detecting the
release of interferon-gamma (IFN-γ) by circulating T cells
following stimulation with antigens unique to Mycobacterium
(M.) tuberculosis and three NTM: M. kansasii, M. szulgai, and
M. marinum (10). IGRA results are unaffected by previous
BCG vaccination.
Guidelines for the use of TST and/or IGRA as a screening
tool for young children are heterogeneous (11–13). There is
currently no consensus about the screening policy for identifying
children at risk of TB infection. The United Kingdom National
Institute for Health and Care Excellence (NICE) (14) and the
Centers for Disease Control (CDC) (7) recommend screening
children younger than 5 years for TB using TST only. The
guidance from the European Center for Disease Prevention and
Control (ECDC) states that IGRA testing should not replace
TST after exposure to an infectious TB case but may be used,
in addition to TST, as part of an overall risk assessment.
Any positive result should be considered. For children with
low risk, without exposure, IGRA can be used to rule out
false positive TST reactions caused by BCG vaccination or
Abbreviations: BCG, Bacillus Calmette–Guérin; IGRA, Interferon gamma release
assay; IFN-γ, interferon-gamma; IU/ml, International Units/milliliter; LTBI,
Latent tuberculosis infection; M., Mycobacterium; mm, millimeter; NTM, Non-
Tuberculous Mycobacteria; number, no; QFT, QuantiFERON R©-TB Gold In-Tube
test; TB, tuberculosis; TST, tuberculin skin test;WHO,WorldHealth Organization.
after exposure to NTM with a two-step approach (8, 15).
This study aims to evaluate the accuracy of IGRA for the
screening of TB infection in children aged <5 years in Belgium,
a low TB prevalence country with <10 cases per 100,000
population (1).
PATIENTS AND METHODS
Children aged 0–5 years assessed for TB between September 2008
and July 2011 at the CHU Saint Pierre, a university-affiliated
hospital located in Brussels, were prospectively included in this
study. TB screening was performed either in the context of
contact with contagious cases in household settings, schools
or day-care centers or as part of immigration screening or
investigations for suspected active TB disease with clinical or
radiological relevant signs.
Clinicians recorded prospectively demographic features,
history of exposure to an active TB disease case, clinical
history and BCG vaccination status (confirmed by reviewing the
immunization record, if available, or by the presence of a scar).
Human immunodeficiency virus serology results were recorded,
if available, but testing was not performed as a part of this study.
Trained nurses performed TST using the Mantoux method
with tuberculin-purified protein derivative RT23 (2 tuberculin
units; Staten Serum Institute) and interpreted the result after
48–72 h by measuring the transversal diameter of induration in
millimeters (mm). A TST result ≥ 5mm was considered positive
for children with recent contact with a TB case and a TST result of
≥10mm for the other children, according to national guidelines
(Table 1) (16, 17).
QuantiFERON-TB Gold-In-Tube (QFT), a third-generation
IGRA test, evaluates the in vitro release of IFN-γ in three
different blood collection tubes. The first tube is coated with TB-
specific Antigen: ESAT-6, CFP-10, and TB7.7. The second tube
is saline, used as a negative control (Nil), that gives information
about background IFN-γ secretion (IU/ml). The third tube is a
positive control (PHA mitogen) that evaluates the global ability
to produce IFN-γ. According to manufacturer’s interpretation
criteria, a QFT value (IU/ml) is considered positive, for an IFN-
γ response to TB Antigen, if significantly above the Nil value
(TBAntigenminus Nil) using the recommended threshold≥0.35
IU/ml and ≥25% of the Nil value. A test is indeterminate if the
Nil value is >8.0 IU/ml or if PHA mitogen value minus Nil value
is <0.5 IU/ml. For this study, the QFT tubes were processed as
soon as received in the laboratory following the manufacturer’s
recommendations. Plasma samples were stored at −20◦C after
incubation for at least 16 h and assays were performed once
a month.
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In the absence of a gold standard to diagnose LTBI, TST was
used as the surrogate reference. When TST was positive or in the
presence of clinical signs, a chest X-ray was performed.
In case of any radiological or clinical suspicion of TB disease,
further investigations were pursued, including microscopy
(auramine staining), molecular testing by polymerase chain
reaction (PCR) and mycobacterial cultures on three consecutive
early-morning gastric aspirate samples in case of suspicion of a
pulmonary TB disease or on other samples accordingly to the
extra-pulmonary site involved.
Children with a negative TST and without any signs
of active TB disease, exposed during the previous 8 weeks
to an infectious TB patient, underwent repeated screening,
including a TST and a QFT, at least 8 weeks after the latest
exposure. During this interval, children received window period
prophylactic treatment. We considered children not infected by
M. tuberculosis if they had a negative TST result more than 8
weeks after the last exposure and if clinical examination provided
no argument for illness.
LTBI was diagnosed in children who had a positive TST,
normal chest X-ray and who remained asymptomatic during the
12-month follow-up period. Active TB disease was confirmed
in case of bacteriologically proven disease and diagnosed as
highly probable in children with TB suggestive clinical symptoms
and/or radiographic findings, and TST positive result with a
response to treatment included in the follow-up. Additional QFT,
TABLE 1 | (Addendum): General interpretation criteria of the tuberculin test*.
Diameter of
the induration
Interpretation
<5mm Negative
5–9mm Negative
Positive
- In case of infection with HIV or severe immune deficiency
- In young children < 5 years of age, who have recently been
in contact with an infectious patient or who are
immune-deprived or who show a clinical manifestation of
active tuberculosis
Doubtful
- In persons ≥5 years of age: in case of close contact with an
infectious tuberculosis patient
- In children < 5 years of age or in persons ≥65 years of age:
in the absence of risk factors
10–17mm Positive
- In case of close contact with an infectious
tuberculosis patient
- And/or when there is an increased risk of infection
or tuberculosis
- In all children, regardless of their age
Doubtful
- In the absence of a risk factor
- And/or in the case of BCG
≥18mm Positive
*Translation from “Recommendations regarding the prevention of tuberculosis in
healthcare facilities” of the Belgian Superior Health Council. 2013 Report Number: HGR
8579 (16).
*This table is under revision and new guidelines will be published in 2019.
during follow-up, were performed whenever venous puncture
was considered necessary for clinical purposes (evaluation
of inflammatory status and/or monitoring of adverse drug
reactions) in children with LTBI or TB disease.
After a 12-month follow-up, based on TST results, symptoms,
investigations and evolution, all children received a final
diagnosis. We compared the results of QFT and TST only if
both tests were performed within a 2-week interval. If the initial
TST result was more than 10mm, it was not repeated, and QFT
controls were compared to the first positive TST.
Data were analyzed using the GraphPad Prism Software
version 7.0b for Windows (GraphPad Software, San Diego,
CA, USA, www.graphpad.com). TST and QFT agreements
were calculated by the kappa-statistic, a measure of
inter-rater agreement between both ratings. The kappa-
statistic measure of agreement was scaled to be 0 when
the amount of agreement was what would be expected
to be observed by chance and 1 if there was perfect
agreement. Indeterminate QFT results were excluded from
the analysis of concordance with TST. A non-parametric
Spearman test analyzed correlations between the TST and
QFT values.
ETHICAL APPROVAL
Oral and/or written consent was obtained from parents or legal
guardians and registered.
RESULTS
We enrolled 66 children in the study. Out of these, six
children were excluded from the final analysis: one child had
a confirmed M. avium infection, one child’s QFT test was
lost during transport, one child’s QFT test was not done
simultaneously with the TST, and three children were lost
during follow-up (Table 2). The median age of the included
children was 19.5 months (range: 14 days−59 months), with
35/60 children (58%) being younger than 2 years. The study
population included 34/60 males (57%), and a minority
of the enrolled children (13/60, 22%) were foreign-born.
None of the children received immunosuppressive therapy,
TABLE 2 | Characteristics of the study population (n = 60 children).
Median age years (age range) 19.5 months
(14 days−59 months)
Male 34/60 (57%)
Age < 2 years 35/60 (58%)
Foreign born 13/60 (22%)
No BCG vaccination 49/60 (83%)
Exposure to tuberculosis
Group 1: Known exposure 51/60(85%)
Group 2: High tuberculosis prevalence country 6/60 (10%)
Group 3: Clinical suspicion (no known contact exposure) 3/60(5%)
BCG, Bacillus Calmette Guerin.
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had a history of LTBI or active TB disease or a chronic
medical condition. BCG vaccination was documented for 11/60
children (18%).
Among the 60 children included in the final analysis, tests
were requested for 51 children due to exposure to a contagious
TB case, for six due to recent immigration from a high TB
prevalence country and for three due to clinical suspicion of
active TB disease (but no known contact exposure) (Figure 1).
At the end of the 12-month follow-up period, among the
subgroup of exposed children (n = 51), we classified 44 (86%)
of them as non-infected, four (8%) as having an active TB disease
and three (6%) as being LTBI.
Reference patient numbers are listed in Table 3. Among
the seven children classified as M. tuberculosis infected (LTBI
and active TB disease combined), the first performed TST was
≥10mm for all but one child, whose diagnosis was confirmed as
active TB disease (patient no. 60 in Table 3). He demonstrated a
negative TST (0mm) at inclusion but turned positive (12mm) at
the second evaluation. Among recently immigrated children, we
classified 5/6 (83%) as non-infected and 1/6 (17%) as LTBI. None
of the children screened for suspected clinical TB were confirmed
to be infected byM. tuberculosis.
Whereas, all children underwent TST at their initial
evaluation, a paired and valid QFT result was available for 55/60
of them (92%). Three children had indeterminate QFT results
and for two others QFT results were not obtained simultaneously
with the TST. A second evaluation was obtained for 35/60
children (58%): for 33/35 children because they were recently
exposed to TB but tested negative on the first TST and for 2/35
children for reasons related to clinical follow-up. At this second
evaluation, two children had indeterminate QFT results, two
had unevaluable samples for a pre-analytical reason (incorrectly
incubated), three had samples not obtained simultaneously with
the TST and two children were not QFT retested. As such, paired
TST/QFT results were available for 26 of these 35 children. For
the QFT analysis, a total of 109 blood samples were taken during
the study from the 60 enrolled patients, of which 12 samples were
excluded for the calculation of agreement.
The second round of TST testing was done, on average, 10
weeks after the first evaluation (between 4 and 33 weeks). Besides,
among these 35 children, 8 had a third (TST/QFT) paired test,
whereas another three infants (5, 6, and 21 months of age at
the time of inclusion) had a fourth paired evaluation and one
child (5 months old) even had a fifth controlled paired test.
These supplemental blood tests have been asked for clinical
purposes. Two children who presented with a TST ≥ 10mm at
the first evaluation were re-evaluated twice for QFT but without
repetition of the TST.
FIGURE 1 | Flowchart of inclusion and classification. Sixty-six children were enrolled in the study. Six children were excluded from analysis: one child had a confirmed
Mycobacterium avium infection, one child’s QFT sample was lost during transport, one child’s QFT was not done simultaneously with the TST, and three children were
lost during follow-up. Among the 60 remaining children, tests were requested in 51 children after exposition to a contagious TB case, in six due to recent immigration
and in three based on a clinical suspicion of TB disease (no known contact exposure). QFT, QuantiFERON®-TB gold in-tube test; TB, tuberculosis; TST, tuberculin
skin test.
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TABLE 3 | Results of all children (n = 60) with QFT/TST results.
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1 F 10 Europe 9.2 No 0 N 0.00 N Yes •
2 M 9 Europe 9.2 No 0 N 0.00 N Yes •
3 F 33 Europe 60 Yes 8 P 0.00 N& 0 N 0.00 N Yes •
4 M 33 Europe 9.2 No 20 P 14.43 P Yes TBa
confirmed

5 M 5 Europe 9.2 No 0 N 0.00 N 0 N N/A NS No •
6 M 14 Europe 9.2 No 0 N 0.28 N No •
7 M 1 Africa 194 Yes 15 P 0.00 N& No LTBI N
8 M 20 Europe 9.2 No 0 N 0.04 N 0 N N/A T 0 N 0.02 N Yes Yes •
9 M 21 Europe 9.2 No 0 N 0.02 N 0 N N/A T 0 N 0.04 N* Yes •
10 M 1 Europe 9.2 No 0 N 0.00 N 0 N 0.00 N No •
11 M 49 Europe 9.2 No 15 P 22.23 P Yes Yes LTBI N
12 F 3 Europe 9.2 No 0 N N/A I 0 N 0.00 N Yes •
13 F 45 Europe 9.2 No 0 N 0.04 N 0 N 0.00 N Yes •
14 M 42 Europe 9.2 No 0 N 0.06 N Yes No •
15 F 60 Europe 9.2 No 0 N 0.00 N Yes No •
16 M 37 Africa 57 Unknown 0 N 0.00 N 0 N 0.04 N Yes •
17 F 19 Africa 57 Unknown 0 N 0.00 N 0 N 0.00 N Yes •
18 F 6 Europe 9.2 Yes 10 P 0.00 N& P 0.00 N P 0.00 N Yes LTBI N
19 F 45 Europe 60 Unknown 0 N 0.02 N Yes •
20 F 6 Europe 9.2 No 0 N N/A I 0 N 0.00 N 0 N 0.00 N Yes •
21 F 47 Europe 9.2 No 0 N 0.00 N 0 N N/A I Yes •
22 F 0 Europe 9.2 No 0 N 0.00 N 0 N Yes No •
23 M 33 Africa 266 Unknown 0 N 0.00 N Yes No •
24 M 58 Africa 266 Unknown 0 N 0.00 N Yes No •
25 F 26 Europe 9.2 No 0 N 0.18 N 0 N 0.61 P $ 0 N 0.00 N Yes •
26 M 12 Europe 60 Unknown 13 P 0.67 P Yes LTBI N
27 F 36 Unknown N/A Unknown 0 N 0.00 N 0 N 0.00 N Yes •
28 M 21 Europe 9.2 No 7 P 0.00 N& 0 N Yes No •
29 F 52 Europe 9.2 No 0 N 0.00 N Yes •
30 M 59 Europe 9.2 No 0 N N/A NS 0 N 0.00 N Yes •
31 M 4 Europe 9.2 No 0 N 0.00 N 0 N N/A I Yes •
32 F 13 Europe 9.2 No 14 P 5.21 P Yes TBa
probable

33 M 6 Europe 9.2 No 0 N 0.00 N 0 N 0.00 N 0 N 2.59 P $* Yes •
34 F 53 Amercia 44 Yes 0 N 0.00 N 0 N 0.09 N Yes •
35 M 1 Europe 9.2 No 0 N o.oo N 0 N 0.00 N Yes •
36 M 31 Europe 9.2 No 0 N 0.00 N 0 N 0.00 N Yes •
37 F 12 Europe 9.2 No 0 N 0.00 N 0 N 0.00 N Yes •
38 F 5 Europe 9.2 No 0 N 0.22 N 0 N 0.00 N 0 N 0.66 P $# Yes •
39 F 6 Europe 72 No 0 N 0.00 N Yes •
40 M 11 Europe 9.2 No 0 N 0.00 N 0 N 0.00 N 0 N 0.00 N Yes •
41 M 8 Europe 9.2 No 0 N 0.01 N 0 N 0.00 N N Yes •
42 M 43 Europe 9.2 No 0 N 0.00 N Yes •
(Continued)
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TABLE 3 | Continued
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43 M 46 Europe 9.2 No 0 N 0.00 N 0 N 0.00 N Yes •
44 F 5 Europe 9.2 No 0 N 0.00 N Yes •
45 M 13 Europe 9.2 No 0 N 0.00 N Yes •
46 M 24 Europe 9.2 No 0 N 0.16 N Yes •
47 M 11 Europe 9.2 No 0 N 0.01 N Yes •
48 F 21 Europe 9.2 No 0 N 0.00 N 0 N 0.00 N Yes •
49 M 29 Europe 13 No 14 P 16.52 P P 18.65 P P 20.59 P Yes TBa
probable

50 M 5 Europe 13 No 0 N 0.00 N 0 N 0.00 N 0 N 0.00 N Yes •
51 F 22 Europe 9.2 No 0 N 0.00 N 0 N 0.00 N Yes •
52 M 3 Europe 9.2 No 0 N 0.06 N 0 N 0.05 N Yes •
53 F 38 Europe 9.2 No 0 N 0.00 N 0 N 0.00 N Yes •
54 F 56 Europe 9.2 No 0 N 0.00 N 0 N 0.00 N Yes •
55 F 10 Europe 9.2 No 0 N 0.16 N 0 N N/A NS Yes •
56 M 32 Europe 9.2 No 0 N 0.12 N 0 N N/A NS Yes •
57 M 46 Unknown N/A No 0 N N/A I Yes •
58 M 6 Europe 9.2 No 0 N 0.00 N Yes No •
59 M 13 Europe 9.2 No 0 N 0.14 N Yes •
60 F 13 Europe 9.2 No 0 N N/A NS 12 P 28.26 P Yes TBa
probable

P $: dlscordant TST–/QFT+ results.
N &: discordant TST+/QFT– results.
*: after this result a fourth paired QFT and TST was done, all negative results.
#: after this result a fourth and fifth paired QFT and TST were done, all negative results.
N, negative; P, positive; I, indeterminate; NS, not simultaneously with TST; T, technical problem (incorrectly incubated); N/A, not applicable for analysis; BCG, Bacillus Calmette–Guerin;
QFT, QuantiFERON®-TB Gold in-tube; TST, tuberculin skin test; LTBI, latent tuberculosis infection; TBa, active disease.
The five children (ages 3, 4, 6, 46, and 47 months)
with indeterminate QFT results following the first or second
evaluation, had a negative TST and were considered as non-
infected at the end of the follow-up period as they tested twice
negative using the TST as the reference, and demonstrated
at least two negative QFT. None of them had a known
immunodeficiency. Reasons for indeterminate results included a
Nil value > 8.00 IU/ml for two children (patients no. 31 and 57)
and a PHA mitogen value minus Nil value of < 0.5 IU/ml for
three children (patients no. 12, 20, and 21).
Among the 97 eligible samples for the test agreement analysis,
the statistical analysis indicated a moderate agreement between
both test results, when applying the cut-offs described in the
methods section. The QFT results achieved a good classification
for 88 samples (Kappa test 0.59, confidence interval 0.35–0.83).
Taking the TST results as a reference, the positive predictive
value of the QFT was 0.72, the negative predictive value was
0.93, the sensitivity of the QFT to identify M. tuberculosis
infected children was 57%, and the specificity was 96% (Table 4).
When we restricted the comparison of TST and QFT to the 79
samples from the 49 children who were not BCG vaccinated
(Table 5), the degree of agreement became substantial (Kappa
test 0.75, confidence interval 0.51−0.98) with 75 concordant
samples (95%). Moreover, the negative predictive value of the
QFT was 0.99.
Three children (patients no. 25, 33, and 38 inTable 3) who had
been exposed and diagnosed as non-infected at the end of follow-
up, had a positive QFT result whereas the simultaneous TST
was negative (TST–/QFT+). Meanwhile, they received window
prophylactic treatment until the second evaluation, 8 weeks after
the latest exposure to infectious TB. Throughout the follow-up,
subsequent QFT and TST controls for these children were all
negative. For one 26-month-old child (patient no. 25), the first
QFT performed at inclusion was negative, whereas the second
result, 6 weeks later, revealed positive and the third, 1 year later,
turned negative. Two other children (patients no. 33 and 38),
respectively, 6 and 5 months old at inclusion, demonstrated
their third QFT to be positive at, respectively, 9 and 14 months
of age, while the two previous QFT results were negative and
the TST stayed negative on the four testings. Extensive clinical
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TABLE 4 | Comparison of tuberculin skin test and QuantiFERON® Gold in-tube
test.
QFT TST
Positive Negative Total
Positive 8 3 11
Negative 6 80 86
Total 14 83 97
Six samples with discordant TST+IQFT– results from four children; three of them were
BCG vaccinated children, one child had a TST value of 7 mm: exposure history to
the assumed index case was not confirmed (smear-negative sputum examination and
subsequently culture negative from the index case).
Three samples with discordant TST–/QFT+ were from three children, their serial testing
of TST and QFT negative at all other evaluations.
Number of observed agreement between QFT and TST: 88 samples (90.72% of
the observations).
Kappa test 0.59, 95% confidence interval 0.35–0.83.
QFT, QuantiFERON® Gold in-tube test; TST, tuberculin skin test.
TABLE 5 | Comparison of tuberculin skin test and QuantiFERON® Gold In-Tube
test (without BCG).
QFT TST
Positive Negative Total
Positive 7 3 10
Negative 1 68 69
Total 8 71 79
Number of observed agreement between QFT and TST: 75 samples (94.94% of
the observations).
Kappa test 0.75, 95% confidence interval 0.52 to 0.98.
QFT, QuantiFERON® Gold In-Tube test; TST, Tuberculin Skin Test.
follow-up of these three children for 2 years indicated that
all of them remained in good health and were considered as
not infected.
Four children (patients no. 3, 7, 18, and 28 in Table 3)
had a total of six samples (6%) which were QFT negative,
while simultaneous TST was positive (TST+/QFT–) (Table 4).
Two of these children (patients no. 3 and 28) had a first TST
induration of, respectively, 8 and 7mm, whereas controls (TST
and QFT) turned negative; both were finally considered as
non-infected. As patient no. 3 had received a BCG vaccine,
we regarded the first TST result as a false positive result.
Patient no. 28, on the contrary, was not BCG vaccinated,
moreover his exposure history to the assumed index case
was not confirmed (smear-negative sputum examination and
subsequently culture negative). As such his first TST result
should also have been a false positive, we considered the
initial positive TST in this child to be a non-specific skin
reaction. The two other children (patients no. 7 and 18 in
Table 3) came from a high TB burden country and had a
record of BCG vaccination. We diagnosed LTBI based on their
TST results.
Among the four children with LTBI, two had concordant
positive paired (TST+/QFT+) test results, and two had
discordant TST+/QFT– test results. Among the children
FIGURE 2 | Correlation of QuantiFERON interferon-γ values (IU/ml) and TST
diameter of induration (mm). The results of the QuantiFERON interferon-γ
values and the TST diameter of induration were compared for 97 samples
including 52 children diagnosed as not infected (•), but 85 samples; five
children with a diagnosis of latent tuberculosis infection (N), but six samples;
four children with a diagnosis of pulmonary TB (), but six samples.
BCG-vaccinated children were identified with a red color, BCG-unvaccinated
children with a black color, and unknown BCG status children with a blue
color. Each dot corresponds to a single sample. The value of the r Spearman
correlation index is 0.36 (95% confidence interval 0.17–0.53).
with a final diagnosis of pulmonary TB, all had concordant
positive (TST+/QFT+) test results on the six collected
paired samples.
To investigate the association between the TST and the QFT
result, we also compared IFN-γ concentrations or the QFT value
(IU/ml) (TB Antigen minus Nil) to the induration size of the
TST (mm) for 97 blood samples (Figure 2). A poor correlation
between both results was obtained, as shown by the Spearman’s
rank correlation coefficient (0.36, 95% confidence interval 0.17–
0.53). However, we observed the highest QFT values in children
with the largest diameter of TST induration.
DISCUSSION
In our study, we evaluated the accuracy of QFT as a screening test
in young children at risk for TB infection, in a low TB prevalence
country. In the absence of a gold standard to diagnose LTBI,
we compared QFT with TST results. Considering TST as the
reference, we observed a moderate agreement between QFT and
TST (90.72%, Kappa 0.59) with 9% of paired (TST/QFT) tests
being discordant. However, in children with no previous BCG
vaccination, there was a good agreement (95%, Kappa 0.75).
Comparative studies in low TB burden countries
demonstrated lower levels of agreement than observed in
our study. Lighter et al. found an overall agreement of 55%
(Kappa 0.17) in children with LTBI, which increased to 72%
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(Kappa 0.31) considering children who had not been BCG-
vaccinated. Agreement was stronger (91%), in the subgroup of
children not vaccinated and presenting a TST > 15 mm (18).
Spicer et al. evaluated the correspondence between TST and
the T-SPOT.TB test, another IGRA, among 107 young adopted
children. Overall agreement was 80.8% (Kappa 0.68); however,
BCG vaccination reports were available only in 72% of the cohort
and an unknown higher BCG coverage in these adoptees could
have influenced the agreement (19).
The accuracy and reliability of IGRAs among young children
are not yet well-defined. Limitations of this test includes, in
comparison to TST: lack of data in very young children, increased
frequency of indeterminate results in children <5 years old (9)
and the inconveniences of doing phlebotomy in small children:
at least two nurses are required and obtaining a minimum blood
volume of 4ml is not always easy in young children.
Indeterminate QFT results are (9, 20) observed in pediatric
populations in 0–35% (18, 21, 22). A high rate of indeterminate
results is described in immune deficient patients, non-TB related
acute infections or active severe TB disease (23). In our cohort
of young children, the rate of indeterminate QFT, following the
manufacturer’s recommendations, was 4.5%. After follow-up, we
finally considered these five children as not infected. Our results
suggest that age per se is not a factor increasing the rate of
indeterminate results.
In this study, four children presented TST+/QFT– discordant
results. For two of them, this was most likely explained by a false
positive TST as the TST turned negative on subsequent testing.
For the two other children, we could not determine if the TST
was false-positive or the QFT false-negative. Both were BCG
vaccinated and came from a high-burden country.
Most experts consider TST+/IGRA– discordant results as
false positive TST results in recent BCG-vaccinated individuals
(24–26). Seddon and colleagues evaluated the impact of BCG
vaccination on TST results and observed that the BCG
vaccination affected the TST response in IGRA-negative children
aged <5 years, but this effect waned rapidly with age (26).
However, in young at-risk children, these TST+/IGRA– could
be due to the low capacity of young children to produce IFN-
γ and other cytokines in response to mycobacterial antigens
(27–30). To overcome underdiagnosis in BCG-vaccinated young
children tested for LTBI, Pavic recommends using both tests
and considering the child infected if either one or both are
positive (25).
Reverse discordant results (3%), TST–/QFT+, were observed
in three children, exposed to a contagious TB case. They
presented, each on one occasion, a positive quantitative QFT
value that ranged from 0.61 to 2.59. Finally, we considered these
children as not infected at the end of the follow-up period. The
positive QFT results were preceded and followed by a negative
QFT result, and the TST was three times negative for all three
children. Reversion of positive QFT results to negative results
have been described previously and may result from transient
immune responses in children exposed to M. Tuberculosis (31).
They have been reported to be more frequent for quantitative
QFT values ranging from 0.35 to 4.00 IU/ml (29, 32).
In this study, the positivity threshold recommended by the
manufacturer, i.e., 0.35 IU/ml, was applied for the QFT value
(TB Antigen minus Nil). However, some discussion had arisen
about the need to adjust the positivity cut-off for the QFT value.
Lombardi and colleagues showed that children <5 years old
with LTBI produced lower levels of INF-γ in response to TB
antigens (median 1.96 IU/ml) than those with active TB (median
10 IU/ml) (29). Similarly, Andrews et al. concluded from the
results of serial QFT testing in young children in a large study in
South Africa, that QFT conversion with values higher than 4.00
IU/ml was associated with a substantially increased risk (28%)
of developing TB disease (32). If we had considered a threshold
of more than 4.00 IU/ml, we wouldn’t have observed any
discordant TST–/QFT+ results. On the one hand, three children
in our cohort who presented TST–/QFT+ results could have
been diagnosed as LTBI considering the QFT-positive testing,
following Pavics recommendations (25). The QFT cut-off of 0.35
IU/ml turned these cases positive (QFT values of 0.61, 0.66, and
2.59) while they would have been negative using a threshold of
more than 4.00 IU/ml. On the other hand, one child (patient
no. 26 in Table 3), 12 months old, originating from Eastern
Europe, without any documented BCG status, and exposed to
a contagious pulmonary TB case, was considered as an LTBI,
based on a positive TST. His QFT test demonstrated a “positive”
quantitative value of 0.69 IU/ml, slightly above the limit but not
as high as other children diagnosed as LTBI or children with TB
disease. If a threshold of >4.00 IU/ml would have been used, this
would give a discordant TST+/QFT– result.
Among other children labeled as LTBI, patient no. 11 also
requires special consideration. Its quantitative QFT value was
as high as those observed in active TB children and far above
the median value presented by Lombardi for LTBI (29). But
only one test was available in this case, during clinical follow-
up there was no suspicion of development of active TB disease.
The distinction between infection and subclinical disease or
imminent progression to TB disease may be blurred. Results
of serial testing turned out to be very informative. Extended
follow-up of children with discordant (TST–/QFT+) results had
low predictive value for TB and were associated with high
rates of reversion (32). In our study, we concluded based on
follow-up testing that these QFT results were most likely false
positive results.
A limitation of this study is that we evaluated the third
generation QFT which differs from the actual fourth generation
of the IGRA QuantiFERON-TB Gold Plus that uses two antigen
tubes (TB1 and TB2) instead of only one. The previous single
tube QFT contained peptides from three different antigens,
ESAT-6, CFP-10, and TB7.7. The two tubes of the new version
only contain peptides from ESAT-6 and CF-10 antigens, but
shorter peptides were added with the hope to detect CD8+ T cell
responses (in TB2 tube) in addition to CD4+ T cell responses
(in TB1 tube). This new version has been marketed with the
prediction that it is more sensitive for the immunocompromised
patient. Literature shows an overall good agreement between
both tests, no prospective studies on young children have been
published yet (33, 34).
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CONCLUSION
In this prospective study of a cohort of children aged <5
years, at high risk of TB in a low TB prevalence country,
QFT, one of the commercially available IGRA tests, proved to
have substantial agreement with TST. Our study population
and observations made us aware of false positive and false
negative QFT results. In this young age group, recent BCG
vaccination seemed to influence TST results and was more
likely associated with false positive TST than with false
negative QFT.
Indeterminate results were observed, but not in high
percentages in otherwise healthy children. Further studies
should help with strengthening our observations, particularly
to evaluate discordant results and the threshold for the
QTF value (TB Antigen minus Nil) to avoid false positive
QFT results.
Currently, in the very young population (<1 year old), we
advise to evaluate both TST and IGRA after the window period of
8 weeks and to continue treatment if one or either test is positive.
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